Press Releases

    • DEC 19 2017

    Oncoceutics Extends Composition of Matter Patent Portfolio to ONC212

    Philadelphia, PA (December 19, 2017) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) issued patent #9,845,324, providing the company with composition of matter protection for ONC212 and several additional small molecules derived from Oncoceutics’ lead compound ONC201. ONC212 is one of the lead follow-on compounds in the company’s development pipeline

    • NOV 13 2017

    Effectiveness of ONC201 in H3 K27M Glioma to be Presented at SNO

    Philadelphia, PA (November 13, 2017) – Oncoceutics, Inc. today announced that five clinical and preclinical presentations on ONC201 and ONC206 for the treatment of high grade gliomas will be presented at the 22nd Annual Scientific Meeting and Education Day of the Society of Neuro-Oncology, held November 16th-19th in San Francisco. The series of presentations describe

    • NOV 03 2017

    ONC201 Trial for Histone Mutant Glioma Begins at NYU

    Philadelphia, PA (November 3, 2017) – Oncoceutics, Inc. announced today that the first patient has been treated in a Phase II clinical trial of ONC201 for patients with recurrent high-grade gliomas that contain a specific mutation called the histone H3 K27M mutation. The trial is led by Andrew Chi, MD, PhD, Chief of Neuro-oncology and

    • OCT 09 2017

    Oncoceutics and MD Anderson Expand Alliance to Cover Imipridone ONC212

    Philadelphia, PA (October 9, 2017) – Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center announced the expansion of their strategic alliance and research collaboration agreement to include the clinical development of ONC212. Since 2015, Oncoceutics and MD Anderson have collaborated on the clinical development of ONC201, the founding member of the imipridone